Neurotology drug developer Otonomy (NSDQ:OTIC) is expanding a Phase 1/2 trial of OTO-413 in patients with difficulty with speech-in-noise tests. In the trial, clinical investigators administer the drug as a single intratympanic injection. The company said that OTO-413 showed promise in improving hearing in a dose escalation efficacy cohort. The randomized, double-blind, placebo-controlled Phase 1/2…
Frequency Therapeutics drug shows promise in restoring hearing in small study
Frequency Therapeutics (Woburn, Mass.) recently announced data related to its experimental FX-322 drug. The small Phase 1/2 study, published in Otology & Neurotology, found hearing improvements in adults with age-related sensorineural hearing loss. At present, there are no FDA-approved drugs for preventing or restoring such hearing loss. However, administering steroids can facilitate recovery of hearing…